Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2016 Mar 1.

Published in final edited form as: Pediatr Res. 2015 Jun 4;78(3):239–246. doi: 10.1038/pr.2015.109

Absence of antibody-mediated responses against AAV after neonatal administration. A) Antibody titers to AAV rh10 capsid proteins were measured (as adults) by ELISA after neonatal injection of AAVrh10 at day 2 of life (■), at day 2 and day 14 (), and at day 2 and day 14 with rh10 and with AAV serotype 9 at day 42 (). Positive control was demonstrated by administering AAVrh10 on day 14 and AAV 9 on day 42 (□). B) Antibody titers to AAV 9 capsid proteins were measured by ELISA after neonatal injection of AAVrh10 at day 2 of life (■), at day 2 and day 14 (), and at day 2 and day 14 with rh10 and with AAV serotype 9 at day 42 (). Positive control was demonstrated by administering AAVrh10 on day 14 and AAV 9 on day 42 (□). Plasma was collected at least 14 days after AAV administration for both sets of studies. (Data are presented as mean + SD.)

Inline graphic — Absence of antibody-mediated responses against AAV after neonatal administration. A) Antibody titers to AAV rh10 capsid proteins were measured (as adults) by ELISA after neonatal injection of AAVrh10 at day 2 of life (■), at day 2 and day 14 (), and at day 2 and day 14 with rh10 and with AAV serotype 9 at day 42 (). Positive control was demonstrated by administering AAVrh10 on day 14 and AAV 9 on day 42 (□). B) Antibody titers to AAV 9 capsid proteins were measured by ELISA after neonatal injection of AAVrh10 at day 2 of life (■), at day 2 and day 14 (), and at day 2 and day 14 with rh10 and with AAV serotype 9 at day 42 (). Positive control was demonstrated by administering AAVrh10 on day 14 and AAV 9 on day 42 (□). Plasma was collected at least 14 days after AAV administration for both sets of studies. (Data are presented as mean + SD.)